These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6454380)

  • 1. Correlation of moxalactam (LY127935) susceptibility tests by disk diffusion and agar plate dilution methods.
    Hall WH; Opfer BJ
    Antimicrob Agents Chemother; 1981 Jan; 19(1):130-3. PubMed ID: 6454380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.
    Hall WH; Opfer BJ; Gerding DN
    Antimicrob Agents Chemother; 1980 Feb; 17(2):273-9. PubMed ID: 6247970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of moxalactam against pathogenic bacteria and its comparison with other antibiotics.
    Perrymann F; Flournoy DJ; Qadri SM
    Chemotherapy; 1983; 29(1):37-42. PubMed ID: 6219865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).
    Barry AL; Thornsberry C; Jones RN; Gerlach EH
    Antimicrob Agents Chemother; 1980 Nov; 18(5):716-21. PubMed ID: 6449905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro activity of moxalactam against 430 clinical, bacterial isolates.
    Digranes A; Benonisen E; Dibb WL; Ostervold B
    Acta Pathol Microbiol Immunol Scand B; 1982 Feb; 90(1):69-72. PubMed ID: 6211028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.
    Lang SD; Edwards DJ; Durack DT
    Antimicrob Agents Chemother; 1980 Mar; 17(3):488-93. PubMed ID: 6252831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.
    Jones RN; Fuchs PC; Sommers HM; Gavan TL; Barry AL; Gerlach EH
    Antimicrob Agents Chemother; 1980 Apr; 17(4):750-6. PubMed ID: 6446880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 Jun; 17(6):937-42. PubMed ID: 6250470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.
    Jorgensen JH; Crawford SA; Alexander GA
    Antimicrob Agents Chemother; 1980 May; 17(5):901-4. PubMed ID: 6249198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro comparison of cefotetan with five other cephalosporins against nosocomial pathogens.
    Daschner FD; Goerke C; Bassler M; Just M
    Chemotherapy; 1982; 28(5):351-4. PubMed ID: 6958416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality control of moxalactam susceptibility disks.
    Barry AL; Preston DA; Jones RN; Gavan TL; Thornsberry C
    J Clin Microbiol; 1983 Jun; 17(6):1032-8. PubMed ID: 6223936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and specific beta-lactamase susceptibility of cefoperazone and moxalactam. Comparison with other cephalosporins.
    Mouton RP; Bongaerts GP; van Gestel M; Bruggeman-Ogle KM
    Chemotherapy; 1981; 27(5):318-24. PubMed ID: 6455258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.
    Reimer LG; Mirrett S; Reller LB
    Antimicrob Agents Chemother; 1980 Mar; 17(3):412-6. PubMed ID: 6448577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro evaluation of LY127935, a new beta-lactam antibiotic with broad-spectrum activity.
    Clarke AM; Zemcov SJ
    J Antimicrob Chemother; 1980 Jul; 6(4):495-8. PubMed ID: 6448833
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative activity of cefotaxime and selected beta-lactam antibiotics against Haemophilus influenzae and aerobic gram-negative bacilli.
    Dabernat HJ; Delmas C
    Rev Infect Dis; 1982; 4 Suppl():S401-5. PubMed ID: 6294790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.
    Borobio MV; Aznar J; Jimenez R; Garcia F; Perea EJ
    Antimicrob Agents Chemother; 1980 Feb; 17(2):129-31. PubMed ID: 6247966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
    Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
    Kurtz TO; Winston DJ; Hindler JA; Young LS; Hewitt WL; Martin WJ
    Antimicrob Agents Chemother; 1980 Oct; 18(4):645-8. PubMed ID: 6255864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides.
    Barry AL; Thornsberry C; Jones RN
    J Antimicrob Chemother; 1980 Nov; 6(6):775-84. PubMed ID: 6254942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.